Lee's Pharma sees H1 net profit attributable to shareholders at HK$85 million-HK$95 million

• Lee’s Pharmaceutical guided for unaudited net profit attributable to shareholders of HK$ 85 million to HK$ 95 million for H1 2026.
• That compares with HK$ 67.2 million in the prior-year period.
• Outlook driven by revenue growth, higher gross margin from a shift toward higher-margin specialty and licensed-in products.
• Manufacturing efficiency gains helped offset higher R&D, selling, distribution, administrative costs, including expenses tied to newly consolidated US operations.
• Interim results for the period are scheduled for publication on Aug. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12301055), on August 26, 2026, and is solely responsible for the information contained therein.